Estrogen Receptor Positive Breast Cancer Clinical Trial
Official title:
PRe-operative ESTradiOl Window of Opportunity Study in Post-Menopausal Women With Newly Diagnosed ER Positive Breast Cancer
Some breast cancers have estrogen receptors (ER+). The investigators know that some ER+ tumours can be cured by hormone therapy alone while other ER+ breast cancers cannot. Currently, there is no perfect way to tell these groups apart nor do the investigators know why some respond when others do not. Research findings suggest that the two types of ER+ breast cancers differ in their response to estrogen with estrogen being toxic to one type and not the other. For those tumours that find estrogen toxic, this may explain why tumours only start to grow when estrogen levels decrease after menopause. The purpose of this study is to see whether a two-week treatment of estrogen equal to pre-menopausal estrogen levels will decrease the rate at which patients' ER+ tumours grow. This will be done by comparing the growth rate in the tissue removed during standard of care surgery after patients have been treated with 7-14 days of estrogen prior to that surgery.
Breast cancer is a heterogeneous disease that includes two ER+ genetic subtypes (luminal A and luminal B) that differ in their response to treatment. Results from the Women's Health Initiative Trial showed that estrogen treated hysterectomized women with no prior history of breast cancer had a significant and persistent decrease in breast cancer incidence when compared to placebo treated participants. This implies that some ER+ breast cancers are in fact growth inhibited by estrogens and are not growth promoted. The hypothesis of this study is that some ER+ breast cancers (luminal A) are actually sensitive (growth inhibited) by estrogen. Objectives: 1. To assess changes in breast cancer proliferation after a 7-14 day trial of estradiol in newly diagnosed estrogen receptor positive post-menopausal breast cancer patients prior to surgery. 2. Exploratory analysis of biologic correlates with comparison to available genotyping tests. This is an open-label single group assignment pilot study for safety/efficacy and exploratory biologic correlates ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT01984138 -
REVIVE: Replens Versus Intra-Vaginal Estrogen for the Treatment of Vaginal Dryness on Aromatase Inhibitor Therapy
|
Phase 2 | |
| Active, not recruiting |
NCT01996046 -
FDG PET/CT in Breast Cancer Bone Mets
|
||
| Completed |
NCT01219699 -
A Study of BYL719 in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA Gene
|
Phase 1 | |
| Active, not recruiting |
NCT02409316 -
[18F]FES PET/CT in Endocrine Refractory Breast Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT01992952 -
Fulvestrant +/- Akt Inhibition in Advanced Aromatase Inhibitor Resistant Breast Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04727632 -
[18F]Fluoroestradiol-PET/CT Companion Imaging Study to the FORESEE Trial
|
Early Phase 1 | |
| Terminated |
NCT02000375 -
A Phase II Study Evaluating the Role of Androgen Receptors as Targets for Therapy of Pre-treated Post-menopausal Patients With ER/PgR-negative/AR-positive or ER and/or PgRpositive/ AR-positive Metastatic Breast Cancer (ARTT)
|
Phase 2 | |
| Active, not recruiting |
NCT02668666 -
Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer
|
Phase 2 | |
| Completed |
NCT02820961 -
Drug-Drug Interaction Study of Entinostat and Exemestane in Postmenopausal Women With ER+ Breast Cancer
|
Phase 1 | |
| Active, not recruiting |
NCT02947685 -
Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer
|
Phase 3 | |
| Terminated |
NCT02823262 -
A Breast Cancer Treatment Decision Aid for Women Aged 70 and Older
|
N/A | |
| Terminated |
NCT02414776 -
Hydroxychloroquine in Metastatic Estrogen Receptor-Positive Breast Cancer Progressing on Hormonal Therapy
|
Phase 1 | |
| Active, not recruiting |
NCT02216786 -
A Randomized Study of AZD2014 in Combination With Fulvestrant in Metastatic or Advanced Breast Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT01765049 -
Breast Density Change Predicting Response to Adjuvant Aromatase Inhibitor
|
||
| Active, not recruiting |
NCT00066690 -
Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer
|
Phase 3 | |
| Completed |
NCT02988986 -
TAK-228 Plus Tamoxifen in Patients With ER-Positive, HER2-negative Breast Cancer
|
Phase 2 |